News >

Chemotherapy Remains Cornerstone of Recurrent Ovarian Cancer Treatment

Caroline Seymour
Published: Tuesday, Apr 09, 2019

Jason A. Konner, MD

Jason A. Konner, MD

Platinum-doublet chemotherapy remains the cornerstone of treatment for patients with platinum-sensitive recurrent ovarian cancer, just as anthracycline- and taxane-based chemotherapy are mainstays for those with platinum-resistant/recurrent disease. However, the availability of bevacizumab (Avastin) warrants careful consideration in terms of which regimen to begin with, explained Jason A. Konner, MD.

 State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, Konner, a medical oncologist at Memorial Sloan Kettering Cancer, shed light on the current treatment landscape for patients with platinum-sensitive and platinum-resistant/recurrent ovarian cancer.

OncLive: What are the key takeaways from major trials in recurrent ovarian cancer?

Konner: First, we established the basis for the platinum doublets. We looked at the trials combining paclitaxel and gemcitabine with carboplatin, which showed superiority to carboplatin by itself. Furthermore, we looked at the head-to-head doublet of liposomal doxorubicin and carboplatin versus paclitaxel/carboplatin in the CALYPSO study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x